Journal of Allergy and Clinical Immunology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Activated sputum eosinophils associated with exacerbations in children on mepolizumab
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 12, 2024 Category: Allergy & Immunology Authors: Gabriella E. Wilson, James Knight, Qing Liu, Ashish Shelar, Emma Stewart, Xiaomei Wang, Xiting Yan, Joshua Sanders, Cynthia Visness, Michelle Gill, Rebecca Gruchalla, Andrew H. Liu, Meyer Kattan, Gurjit K. Khurana Hershey, Alkis Togias, Patrice M. Becker, Source Type: research

Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemia
Antibody deficiencies are the most prevalent cause of inborn errors of immunity accounting for>50% of cases. Among these, X-linked agammaglobulinemia (XLA) represents one of the most severe forms, affecting around 1:100,000 newborn males.1 XLA arises from mutations in the gene encoding BTK, a nonreceptor tyrosine kinase, belonging to the Tec family, that promotes the maturation of B cells in the bone marrow and their activation in the periphery.2,3 At the pro –B-cell stage, the expression of BLNK, Igα, Igβ, and the RAG1- and RAG2-mediated production of Igμ lead to cell surface expression of the pre–B-cell receptor. ...
Source: Journal of Allergy and Clinical Immunology - March 11, 2024 Category: Allergy & Immunology Authors: Sameer Bahal, Marta Zinicola, Shefta E Moula, Thomas E. Whittaker, Andrea Schejtman, Asma Naseem, Elena Blanco, Winston Vetharoy, Yi-Ting Hu, Rajeev Rai, Eduardo Gomez-Castaneda, Catarina Cunha-Santos, Siobhan O. Burns, Emma C. Morris, Claire Booth, Giand Source Type: research

Hematopoietic stem cell gene editing rescues B cell development in X-linked agammaglobulinemia
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 11, 2024 Category: Allergy & Immunology Authors: Sameer Bahal, Marta Zinicola, Shefta E. Moula, Thomas E. Whittaker, Andrea Schejtman, Asma Naseem, Elena Blanco, Winston Vetharoy, Yi-Ting Hu, Rajeev Rai, Eduardo Gomez-Castaneda, Catarina Cunha Santos, Siobhan O. Burns, Emma C. Morris, Claire Booth, Gian Source Type: research

Overlap of Eosinophilic Esophagitis with Inborn Errors of Immunity and Immune Dysregulation
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 9, 2024 Category: Allergy & Immunology Authors: Gregory Constantine, Paneez Khoury Source Type: research

Nasopharyngeal microbiota in children is associated with severe asthma exacerbations
Asthma, one of the most common noncommunicable childhood diseases, is characterized by a (sub)acute worsening of symptoms called exacerbation. Exacerbations can be triggered by exposure to allergens, tobacco smoke, air pollution, or viral infections.1 The severity of these exacerbations ranges from mild and manageable at home to severe exacerbations requiring hospitalization and potentially admission to the intensive care unit (ICU).1 Risk factors for ICU admission in children with an asthma exacerbation include older age,2,3 tobacco smoke exposure, and symptoms for over a week before presentation. (Source: Journal of Alle...
Source: Journal of Allergy and Clinical Immunology - March 8, 2024 Category: Allergy & Immunology Authors: Gina J. van Beveren, Wouter A.A. de Steenhuijsen Piters, Shelley A. Boeschoten, Sam Louman, Mei Ling Chu, Kayleigh Arp, Pieter L. Fraaij, Matthijs de Hoog, Corinne Buysse, Marlies A. van Houten, Elisabeth A.M. Sanders, Peter J.F.M. Merkus, Annemie L. Boeh Source Type: research

Nasopharyngeal microbiota in children is associated with severe asthma exacerbations.
The respiratory microbiome has been associated with the etiology and disease course of asthma. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 8, 2024 Category: Allergy & Immunology Authors: Gina J. van Beveren, Wouter A.A. de Steenhuijsen Piters, Shelley A. Boeschoten, Sam Louman, Mei Ling Chu, Kayleigh Arp, Pieter L. Fraaij, Matthijs de Hoog, Corinne Buysse, Marlies A. van Houten, Elisabeth A.M. Sanders, Peter J.F. M. Merkus, Annemie L. Boe Source Type: research

Learning from nemolizumab: A  promising therapy for prurigo nodularis
A recent phase 3 clinical trial (OLYMPIA 2) of nemolizumab, an anti –IL-31RA mAb for prurigo nodularis (PN), met the key primary end points of efficacy at week 16 and demonstrated benefit across all 5 secondary end points. Some of the more striking results were at the early time point of week 4, with significantly more patients reaching at least a 4-point reductio n in the Peak Pruritus Numerical Rating Scale itch score, almost complete itch relief (Peak Pruritus Numerical Rating Scale  (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Brian S. Kim Tags: Editorial Source Type: research

A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
Systemic allergic reactions (sARs) following coronavirus disease 2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than after traditional vaccines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Muhammad B. Khalid, Ellen Zektser, Eric Chu, Min Li, Joanna Utoh, Patrick Ryan, Hanna S. Loving, Roa Harb, Robbie Kattappuram, Lindsay Chatman, Stella Hartono, Estefania Claudio-Etienne, Guangping Sun, Edward P. Feener, Zhongbo Li, Samuel K. Lai, Quang Le Source Type: research

Learnings from Nemolizumab: A Promising Therapy for Prurigo Nodularis
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Brian S. Kim Source Type: research

Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Tarun Keswani, Nicole A. LaHood, Orlee Marini-Rapoport, Bijoya Karmakar, L éna Andrieux, Brian Reese, Sunny L. Sneed, Lars C. Pedersen, Geoffrey A. Mueller, Sarita U. Patil Source Type: research

Early Skin Inflammatory Biomarker is Predictive of Development and Persistence of Atopic Dermatitis in Infants
The STOP AD study, a randomized, open-label trial evaluating the effect of short-term (first four postnatal days to 8 weeks) skin barrier protection using AVEENO ® Dermexa Fast& Long-Lasting Balm in infants with a parent with allergic disease, demonstrated decreased cumulative incidence and decreased prevalence of AD at 12 months of age. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Georgios N. Stamatas, Takahiro Sato, Carol N í Chaoimh, Thierry Oddos, Richard Insel, Jonathan O’B. Hourihane, Alan D. Irvine Source Type: research

“A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination”
Systemic allergic reactions (sARs) following coronavirus disease-2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than traditional vaccines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Muhammad B. Khalid, Ellen Zektser, Eric Chu, Min Li, Joanna Utoh, Patrick Ryan, Hanna S. Loving, Roa Harb, Robbie Kattappuram, Lindsay Chatman, Stella Hartono, Estefania Claudio-Etienne, Guangping Sun, Edward P. Feener, Zhongbo Li, Samuel K. Lai, Quang Le Source Type: research

Atopic dermatitis phenotype affects expression of atopic diseases despite similar mononuclear cell cytokine response
The atopic march refers to the coexpression and progression of atopic diseases in childhood, often beginning with atopic dermatitis (AD), although children may not progress through each atopic disease. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Mohamed H. Taki, Kristine E. Lee, Ronald Gangnon, James E. Gern, Robert F. Lemanske, Daniel J. Jackson, Anne Marie Singh Source Type: research

Skin Biomarkers Predict the Development of Food Allergy in Early Life
Lipid and cytokine levels in the stratum corneum at the age of 2 months selectively predict with high probability the future onset of food allergy up to the age of 2 years. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Evgeny Berdyshev, Jihyun Kim, Byung Eui Kim, Elena Goleva, Taras Lyubchenko, Irina Bronova, Anna Sofia Bronoff, Olivia Xiao, Sehun Jang, Sanghee Shin, Jeongmin Song, Jiwon Kim, Sukyung Kim, Boram Park, Kyunga Kim, Suk-Joo Choi, Soo-Young Oh, Kangmo Ahn, D Source Type: research

Loss-of-phosphorylation of IKZF1 results in gain-of-function associated with immune dysregulation
Capsule summary: A novel heterozygous mutation T398M in IKZF1 was identified in two patients with immune dysregulation symptoms. Our study shows that this mutation by impacting the phosphorylation of IKZF1 represents a novel gain-of-function mechanism by loss-of-phosphorylation (GOF-LOP). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Akihiro Hoshino, Beno ît Heid Picard, Sophia Polychronopoulou, Charikleia Kelaidi, Saba Azarnoush, Sven Kracker, Frédéric Rieux-Laucat, David Boutboul, Sylvain Latour Source Type: research